Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM trial of Tasigna versus dacarbazine in c-Kit mutated advanced melanoma
NL-OMON34305Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Tasigna with dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Dec 2010; status: active, not recruiting.
02
Drugs
nilotinibdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON34305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34305.